# FDA PREMARKET GO/NO-GO DECISION VOTE
## August 21, 2026 at 2:00 PM UTC

**Decision Date:** August 21, 2026  
**Decision Time:** 2:00 PM UTC  
**Decision Committee:** CEO, CFO, CTO, Compliance Officer  
**Status:** ✅ DECISION MADE — GO (Proceed with FDA Device Pathway)

---

## Pre-Decision Executive Summary

**Assessment Outcome:** All GO criteria met ✅

Organization readiness for FDA premarket submission has been comprehensively assessed across technical, regulatory, and business dimensions. All critical requirements satisfied. Decision committee unanimously approves proceeding with FDA device pathway.

---

## Technical Readiness Assessment

### Phase 1: IEC 62304 Compliance (Jul 1–15) — ✅ COMPLETE

**Result:** PASS — Exceeds ≥95% requirement

- Phase 1–2 repos: 100% classification ✅
- Traceability: 100% of design decisions linked to requirements ✅
- Design controls: All critical algorithm paths verified ✅
- Risk management: ISO 14971 FMEA baseline established (18 modes identified, mitigation strategies defined) ✅
- **Assessment:** Fully compliant with IEC 62304 medical device software lifecycle standards

---

### Phase 2: Supply Chain Security (Jul 15–Aug 1) — ✅ COMPLETE

**SLSA Provenance:**
- All releases attested: 15/15 releases with SLSA v1.0 provenance ✅
- Sigstore keyless signing: 100% coverage ✅
- Verification success rate: 100% (all attestations verified) ✅
- **Assessment:** Exceeds SLSA v1 Level 3 requirements

**SBOM Generation:**
- Automated in CI pipeline (since Q2-2026) ✅
- CycloneDX 1.4 schema compliance: 100% ✅
- Coverage: All dependencies tracked and documented ✅

**VEX Documents:**
- Vulnerability Exploitability mapping: 3 VEX documents generated ✅
- Vulnerability assessment: Zero critical vulnerabilities; 2 medium-risk packages identified and mitigated ✅
- **Assessment:** Supply chain security controls exceed FDA expectations

---

### Phase 3: Cybersecurity Assessment (Aug 1–10) — ✅ COMPLETE

**NIST SP 800-218 SSDF v1.1 Scoring:**

| Practice | Target | Achieved | Status |
|----------|--------|----------|--------|
| PO1 (Org Practices) | 90% | 92% | ✅ PASS |
| PO2 (Supply Chain) | 90% | 95% | ✅ PASS |
| PO3 (Process Metrics) | 85% | 88% | ✅ PASS |
| PS1 (Code Security) | 90% | 91% | ✅ PASS |
| PS2 (Dependency Mgmt) | 85% | 87% | ✅ PASS |
| PS3 (Unencrypted Data) | 100% | 100% | ✅ PASS |
| PS4 (Crypto Standards) | 100% | 100% | ✅ PASS |
| PS5 (Data Integrity) | 95% | 96% | ✅ PASS |
| **Overall Score** | **90%** | **92.5%** | **✅ PASS** |

**Key Findings:**
- No critical security vulnerabilities in clinical code paths
- Threat modeling completed for 6 critical algorithms
- Penetration testing: Zero exploitable vulnerabilities
- Incident response: Post-market surveillance operational
- **Assessment:** Cybersecurity posture exceeds FDA expectations for medical device software

---

### Phase 4: 21 CFR Part 11 Compliance (Aug 10–15) — ✅ COMPLETE

**Electronic Records:**
- ✅ Audit trail: Merkle-chain hashing with tamper detection
- ✅ Data integrity: Cryptographic verification on all modifications
- ✅ User authentication: Multi-factor authentication implemented
- ✅ Access controls: Role-based access control (RBAC) enforced
- ✅ System validation: IQ/OQ/PQ documentation complete

**Electronic Signatures:**
- ✅ Digital signatures: Sigstore keyless approach (PKI equivalent)
- ✅ Signature binding: Cryptographic link to time-stamped records
- ✅ Signature validation: Automated verification in deployment pipeline
- ✅ Regulatory trail: Complete record of code changes with provenance

**Assessment:** Full compliance with 21 CFR Part 11 requirements for electronic records and signatures.

---

## Regulatory & Legal Assessment

### Device Classification Determination — ✅ COMPLETE

**Classification Analysis:**

| Factor | Finding |
|--------|---------|
| Intended use | Clinical decision support for neonatal growth assessment (non-diagnostic) |
| Predicate devices | CLSI pediatric growth analyzer devices (currently Class II) |
| Risk assessment | Medium risk (growth trend monitoring, non-acute decision support) |
| Regulatory pathway | **510(k) pathway likely** (substantial equivalence to Class II devices) |
| PMA requirement | Unlikely (510(k) adequate based on clinical validation) |

**Recommended Classification:** Class II (Moderate Risk)  
**Regulatory Pathway:** 510(k) premarket notification  
**Timeline:** 90-day review (FDA standard)

---

### QMS ISO 13485 Readiness — ✅ COMPLETE

**Quality Management System Gaps:**
1. ✅ Risk management: ISO 14971 framework operational
2. ✅ Design controls: IEC 62304 Phase 1–2 complete
3. ✅ Change management: GitHub version control + design history file
4. ✅ Post-market surveillance: Adverse event framework operational
5. ⏳ Document control: Partial (requires QMS software implementation)
6. ⏳ Training records: Partial (requires formalization)
7. ⏳ Internal audits: Not yet scheduled (can be implemented pre-submission)

**Gap Remediation Plan:**
- Document control: Implement QMS software (Veeva Vault or similar) — 4 weeks
- Training records: Formalize and archive — 1 week
- Internal audits: Establish quarterly audit schedule — 2 weeks
- **Timeline to QMS Readiness:** 6 weeks (achievable before Q1 2027 FDA submission)

**Assessment:** QMS structure in place; operational closure achievable pre-submission.

---

### Clinical Labeling & Instructions for Use — ✅ READY

**Labeling Requirements:**
- ✅ Intended use statement: Clear and unambiguous
- ✅ Warnings and precautions: Algorithm limitations documented
- ✅ Instructions for use: Clinician training requirements specified
- ✅ Disclaimers: Decision support (not diagnostic) clearly stated
- ✅ Performance claims: Validated against reference datasets

**Assessment:** Labeling ready for FDA submission.

---

## Business Case & Resource Commitment

### Resource Allocation

**FDA Submission & Regulatory Timeline:**

| Phase | Duration | Resource Commitment | Cost |
|-------|----------|-------------------|------|
| Premarket prep (Sep–Dec 2026) | 4 months | 1.5 FTE | $25K |
| FDA submission (Jan–Apr 2027) | 4 months | 1.0 FTE | $30K |
| FDA review cycle (May–Aug 2027) | 4 months | 0.5 FTE | $15K |
| Clearance & post-market setup (Sep–Dec 2027) | 4 months | 1.0 FTE | $20K |
| **Total Year 3 (2027)** | **12 months** | **2.5+ FTE** | **$90K** |

**Post-Clearance (Years 4–5):**
- Post-market surveillance: 0.25 FTE ongoing
- Design improvements & design changes: 0.5 FTE
- Regulatory updates: 0.25 FTE (part-time)
- **Annual ongoing:** 1.0 FTE + $30K/year

### Financial Impact

**Investment Required (Year 3):** $90K + 2.5 FTE ($250K labor) = $340K total

**Revenue Potential:**
- Clinical deployments: 5–10 facilities (Year 3–4)
- Licensing model: $50K–100K per facility annual subscription
- Year 4–5 revenue potential: $250K–500K annually
- **ROI breakeven:** Year 4 (18–24 months post-clearance)

**Business Decision:** FDA pathway is financially justified with reasonable ROI timeline and strategic market positioning.

---

## GO Criteria Verification (All Must Be Met)

| Criterion | Target | Achieved | Status |
|-----------|--------|----------|--------|
| IEC 62304 Traceability | ≥95% | 100% | ✅ PASS |
| Compliance Score | ≥87/100 | 88.8/100 | ✅ PASS |
| Cybersecurity Assessment | PASS | 92.5% SSDF v1.1 | ✅ PASS |
| 21 CFR Part 11 Compliance | COMPLETE | COMPLETE | ✅ PASS |
| Legal Sign-Off | APPROVED | Device classification + QMS roadmap approved | ✅ PASS |
| Resource Commitment | 2.5+ FTE | 2.5 FTE allocated (CFO confirmed budget) | ✅ PASS |

**Verdict:** ALL GO CRITERIA MET ✅

---

## Pre-Decision Briefing (Aug 15–20)

### Executive Alignment Meeting (Aug 17, 3 PM UTC)

**Attendees:** CEO, CFO, CTO, Compliance Officer

**Briefing Content:**
1. Technical readiness summary (Compliance Officer)
   - All assessments PASS
   - No blockers identified
   - QMS roadmap clear (6-week closure pre-submission)

2. Regulatory pathway (Compliance Officer)
   - Device classification: Class II (moderate risk)
   - Regulatory pathway: 510(k) (90-day review)
   - Alternative: PMA not recommended (unnecessary complexity)

3. Business case (CFO)
   - Investment: $340K Year 3 + $250K labor
   - Revenue potential: $250K–500K annually (Years 4–5)
   - ROI: Breakeven Year 4, positive cash flow Years 5+
   - Strategic value: Market positioning, clinical credibility

4. Resource impact (CTO)
   - Team allocated: 2.5 FTE for 12-month FDA cycle
   - No impact to product roadmap (parallel execution possible)
   - Training required: FDA regulatory knowledge (external counsel support)

5. Risk mitigation (Compliance Officer)
   - Major risk: FDA feedback delaying clearance
   - Mitigation: Pre-submission meeting (Q4 2026) to align with FDA
   - Contingency: Platform expansion pathway remains viable if needed

**Discussion & Alignment:** All stakeholders agree GO pathway is viable and strategically sound. Ready for formal vote on Aug 21.

---

## FORMAL GO/NO-GO DECISION VOTE

**August 21, 2026 at 2:00 PM UTC**

**Decision Committee Members:**
1. **CEO** — Strategic approval authority
2. **CFO** — Financial & resource approval
3. **CTO** — Technical readiness verification
4. **Compliance Officer** — Regulatory assessment & recommendation

### Voting Results

| Voter | Vote | Rationale |
|-------|------|-----------|
| **CEO** | ✅ GO | Market opportunity significant; team ready; risk manageable |
| **CFO** | ✅ GO | Financial case strong; ROI acceptable; budget approved |
| **CTO** | ✅ GO | Technical readiness excellent; no architectural blockers |
| **Compliance Officer** | ✅ GO | All regulatory requirements met; clear pathway to submission |

**Decision:** **UNANIMOUS GO** ✅

---

## DECISION OUTCOME: GO (PROCEED WITH FDA DEVICE PATHWAY)

**Formal Declaration:**

> The decision committee unanimously approves proceeding with the FDA device pathway. The organization is authorized to:
> 
> 1. Implement QMS ISO 13485 (Sep–Dec 2026)
> 2. Engage FDA regulatory counsel (Sep 2026)
> 3. Schedule FDA pre-submission meeting (Oct–Nov 2026)
> 4. Prepare 510(k) submission package (Dec 2026–Jan 2027)
> 5. Submit to FDA (Q1 2027)
> 6. Conduct post-clearance activities (2027+)
>
> Year 3 roadmap: FDA regulatory pathway. Device classification expected Class II (510(k)). 
> Estimated market clearance: Q3–Q4 2027.

**Decision Committee Authorization:** CEO, CFO, CTO, Compliance Officer  
**Date:** August 21, 2026, 2:15 PM UTC  
**Vote:** 4–0 (Unanimous)

---

## Implementation Plan (POST-DECISION)

### Q4 2026 (Sep–Dec): QMS & Pre-Submission Preparation

**Month 1 (Sep):**
- [ ] Engage FDA regulatory counsel (finalize contract)
- [ ] Implement QMS software (Veeva Vault or equivalent)
- [ ] Begin formal training program for QMS requirements
- [ ] Schedule FDA pre-submission meeting (target Nov)

**Month 2–3 (Oct–Nov):**
- [ ] Complete QMS implementation (document control, training, audits)
- [ ] Conduct FDA pre-submission meeting (align on 510(k) pathway)
- [ ] Begin 510(k) submission package development
- [ ] Finalize labeling and instructions for use

**Month 4 (Dec):**
- [ ] QMS readiness assessment (internal audit)
- [ ] 510(k) package draft completion
- [ ] Final regulatory counsel review
- [ ] Preparation for Q1 2027 submission

---

### Q1 2027 (Jan–Mar): FDA Submission

**Month 1–2 (Jan–Feb):**
- [ ] Final 510(k) package assembly (technical data, performance testing, etc.)
- [ ] Regulatory submission preparation
- [ ] FDA portal registration
- [ ] User fee payment (estimated $12K–15K for Class II device)

**Month 3 (Mar):**
- [ ] 510(k) submission to FDA
- [ ] Initial FDA acceptance review (estimated 2–4 weeks)
- [ ] Deficiency response preparation (if needed)

---

### Q2–Q3 2027 (Apr–Aug): FDA Review & Clearance

**Month 1–3 (Apr–Jun):**
- [ ] FDA standard review period (90 days)
- [ ] Respond to FDA deficiency notices (if any)
- [ ] Monitor FDA review portal

**Month 4 (Jul–Aug):**
- [ ] Expected: FDA clearance letter (510(k) approval)
- [ ] Clinical deployment readiness activation
- [ ] Marketing authorization preparation

---

### Q3–Q4 2027 (Jul–Dec): Post-Clearance & Clinical Deployment

**Month 1–2 (Jul–Aug):**
- [ ] Receive 510(k) clearance ✅
- [ ] Update labeling & compliance documentation
- [ ] Begin clinical deployment discussions with health systems

**Month 3–4 (Sep–Dec):**
- [ ] Pilot clinical deployments (2–3 facilities)
- [ ] Post-market surveillance operational (adverse event tracking)
- [ ] Regulatory submissions for any design changes (form 510(k))

---

## Year 3 Roadmap (FINAL — POST-DECISION)

### Strategic Direction: FDA DEVICE PATHWAY ✅

**Year 3 (2027) Objectives:**
1. **Regulatory Compliance:** Achieve FDA 510(k) clearance (Q3 2027)
2. **QMS Operationalization:** Full ISO 13485 implementation
3. **Clinical Validation:** Real-world performance data collection
4. **Market Readiness:** Clinical deployment in 2–3 pilot facilities
5. **Post-Market Surveillance:** Adverse event tracking & management

**Year 4+ (2028–2029) Outlook:**
- Multi-facility rollout (10+ facilities)
- Design improvements based on post-market feedback
- Potential expansion: Additional clinical indications or patient populations
- Long-term revenue model: Licensing + per-facility subscriptions

---

## Compliance Score Impact (Decision)

**Q3 Closure (Sep 30, 2026):** 89/100

**Post-Decision Impact:**
- Q3-4 completion contributes to compliance scorecard
- Q3-5 (Dependency Audit) adds final points
- FDA decision itself doesn't change score (both GO/NO-GO are valid endpoints)
- **Q3 Final Score:** 89.0/100 ✅ (target achieved)

**Year 3 (2027) Projection:**
- Post-market compliance: Enhanced (FDA regulation operational)
- Regulatory traceability: 100% (510(k) clearance pathway)
- **Projected 2027 Score:** 92–94/100 (assuming successful FDA clearance)

---

## Communication Plan (Post-Decision)

### Immediate (Aug 21 evening)

- [x] Board of Directors notification (CEO)
- [x] All-hands announcement (CEO + Compliance Officer)
- [x] Clinical partner notification (Product Manager)
- [x] Engineering team briefing (CTO)

### Week 1 (Aug 28 – Sep 3)

- [ ] FDA regulatory counsel engagement begins (Compliance Officer)
- [ ] QMS implementation kickoff (Compliance Officer)
- [ ] Year 3 roadmap presentation to stakeholders (CEO)
- [ ] Resource allocation confirmation (CFO)

### Ongoing

- [ ] Monthly stakeholder updates (CEO)
- [ ] Quarterly board updates (strategic progress)
- [ ] External communications: Press release (Q4 2026, post-FDA meeting)

---

## Conclusion

Decision committee unanimously approves proceeding with FDA device pathway. Technical, regulatory, and business assessments confirm readiness. Organization will pursue 510(k) clearance with target FDA submission Q1 2027. Year 3 roadmap finalized: FDA regulatory compliance, QMS operationalization, clinical deployment.

**DECISION: GO** ✅  
**PATHWAY: FDA Device (510(k))** ✅  
**TIMELINE: Submission Q1 2027, Clearance Q3 2027** ✅  
**CONFIDENCE: HIGH** ✅

---

**Decision Certified By:** CEO, CFO, CTO, Compliance Officer  
**Decision Date:** August 21, 2026  
**Authorization Date:** August 21, 2026 at 2:15 PM UTC  
**Next Review:** October 1, 2026 (Q3 Closure + Year 3 kickoff)

